PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Internal Medicine and Nephrology Unit, Department of Life, Health & Environmental Sciences, University of L\'Aquila, L\'Aquila, Italy alessia.alunno82@gmail.com.\', \'Institute of Infection, Immunity and Inflammation, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.\', \'Department of Rheumatology, Université Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, INSERM UMR1184, Le Kremlin-Bicêtre, France.\', \'Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & The NIHR Leeds Biomedical Research Centre, Chapel Allerton Hospital, Leeds, UK.\', \'Library & Evidence Research Centre, Medical Education, Leeds Teaching Hospitals NHS Trust, Leeds UK, Leeds, UK.\', \'National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC), University College London Hospitals (UCLH) NHS Foundation Trust, London, UK.\', \'Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, UK.\', \'Centre for Rheumatology & Department of Neuromuscular Diseases,University College London, London, UK.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • e00189910.1136/rmdopen-2021-001899
?:hasPublicationType
?:journal
  • RMD open
is ?:pmid of
?:pmid
?:pmid
  • 34725262
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.169
?:rankingScore_hIndex
  • 13
is ?:relation_isRelatedTo_publication of
?:title
  • Immunomodulatory therapies for the treatment of SARS-CoV-2 infection: an update of the systematic literature review to inform EULAR points to consider.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all